Resistance of <i>Acinetobacter baumannii</i> Complex Clinical Isolates to Sulbactam-Durlobactam: A Systematic Review of Data from In Vitro Studies.

ABSTRACT:

Introduction

Due to the limited therapeutic options for patients with Acinetobacter baumannii complex infections, a new combination antimicrobial agent, sulbactam-durlobactam, has been developed. In this systematic review, we evaluated the available data on the resistance of A. baumannii complex clinical isolates to sulbactam-durlobactam.

Methods

We performed a thorough search of four databases for relevant studies. The Clinical and Laboratory Standards Institute (CLSI) sulbactam-durlobactam breakpoint for A. baumannii complex susceptibility was used (MIC value ≤4 mg/L). Data on the presence of genes of various β-lactamases were also analyzed.

Results

From 182 identified articles, 84 were thoroughly screened. Data extraction was performed on 20 ar

SUBMITTER: Falagas ME 

PROVIDER: S-EPMC12566789 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature